TScan Therapeutics Inc.

NASDAQ: TCRX · Real-Time Price · USD
1.84
0.03 (1.66%)
At close: Aug 15, 2025, 12:29 PM

TScan Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
178.69M 133.36M 120.03M 161.41M
Short-Term Investments
111.42M 58.69M n/a n/a
Long-Term Investments
n/a n/a 5.04M 5.2M
Other Long-Term Assets
6.8M 6.68M 4.83M n/a
Receivables
n/a n/a n/a n/a
Inventory
n/a n/a n/a n/a
Other Current Assets
2.61M 2.19M 4.1M 4.25M
Total Current Assets
292.72M 194.24M 120.03M 165.65M
Property-Plant & Equipment
71.6M 71.23M 69.2M 17.26M
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
78.4M 77.91M 79.06M 22.45M
Total Assets
371.12M 272.15M 199.09M 188.11M
Account Payables
4.28M 2.37M 2.91M 1.76M
Deferred Revenue
11.7M 10.14M 3.87M 11.41M
Short-Term Debt
4.57M 3.35M 3.68M 1.65M
Other Current Liabilities
2.35M 5.9M 1.11M 2.27M
Total Current Liabilities
35.96M 29.82M 17.3M 21.34M
Long-Term Debt
32.07M 26.7M 29.29M n/a
Other Long-Term Liabilities
135K n/a 49K 97K
Total Long-Term Liabilities
94.19M 91.46M 82.35M 5.99M
Total Liabilities
130.15M 121.28M 99.66M 27.33M
Total Debt
97.38M 92.43M 85.98M 6.04M
Common Stock
5K 5K 3K 3K
Retained Earnings
-375.1M -247.6M -158.38M -92.16M
Comprehensive Income
51K n/a -0.00 -188.11M
Shareholders Equity
240.97M 150.87M 99.43M 160.78M
Total Investments
111.42M 58.69M 5.04M 5.2M